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Sir, 
 
We read with great interest the leading article regarding integrase inhibitors in the treatment of 
HIV-1 infection recently published in JAC,
1
 where Powderly clearly analyses some clinical 
situations for these drugs. Tuberculosis (TB) remains a problem among HIV-infected patients, and 
the utilization of rifampicin as part of TB treatment limits the use of some antiretroviral treatments 
(ARTs). Traditionally this problem has been solved with the use of rifabutin [if protease inhibitors 
(PIs) were required as part of ART] or with ART regimens containing only reverse transcriptase 
inhibitors. 
 
Rifampicin is a potent inducer of the UGT1A1 enzyme, the principal route of elimination of 
raltegravir. Pharmacokinetic studies in healthy volunteers
2
 and in HIV-infected patients with TB
3
 
have been performed. In them, the AUC of raltegravir, with the usual dose (400 mg twice daily), 
was reduced by 40% due to UGT1A1 induction by rifampicin. Doubling the dose of raltegravir 
(800 mg twice daily) offset this effect, resulting in an increase in the AUC of 27%. 
 
Recently Merck reported initial results from the MK-0518-071 study in which two doses of 
raltegravir were compared, 400 mg twice daily versus 800 mg once daily, in combination with 
tenofovir/emtricitabine in adult treatment-naive HIV-1-infected patients. After 48 weeks, 
raltegravir once daily did not demonstrate non-inferiority to the regimen with raltegravir twice 
daily. These results suggest that there could be a high risk of virological failure if levels of 
raltegravir are too low. 
 
Herein we report our experience with eight HIV-positive patients diagnosed with TB and 
treated with rifampicin-containing tuberculostatic regimens and raltegravir-containing ART. The 
median age was 47 years (range 33–49) and six of the patients were men (75%). Risk factors for 
HIV infection were as follows: six injection drugs users; and two men who have sex with men. 
The CDC categories, before the diagnosis of TB, were as follows: category A, 4; category B, 1; 
and category C, 3. Median follow-up of HIV was 15 years (range 1–21) and 6 patients had 
hepatitis C virus (HCV) co-infection. Four were receiving methadone maintenance treatment. 
  
At the diagnosis of TB, four patients were undergoing ART, and all treatments included 
boosted PIs (three atazanavir/ritonavir and one darunavir/ritonavir); all of these patients had HIV-
RNA  <20 copies/mL and the median CD4 count was 332 cells/mm3 (range 236–589). They did 
not interrupt ART, but the boosted PI was changed for raltegravir (800 mg twice daily) and 
continued with the same backbone (three tenofovir/emtricitabine and one abacavir/lamivudine). 
For the four patients not on ART, the mean HIV-RNA was 5 ± 0.8 log10 copies/mL and the median 
CD4 count was 118 cells/mm
3
 (range 9–224). This group started with ART 56 ± 22 days after 
beginning anti-TB drugs; the ART was tenofovir/emtricitabine and raltegravir (800 mg twice 
daily) in all cases. 
 
The location of TB, treatment and outcome are shown in Table 1. During the follow-up, no 
cases of immune reconstitution inflammatory syndrome were found. All patients were monitored 
at the beginning of TB treatment in order to discard toxicity, mainly hepatic and myopathy, and 
every 2 or 3 months. The safety profile of TB treatment and ART was good; no adverse events due 
to TB treatment and ART were documented. It was not necessary to stop or change any of the 
drugs, and all the subjects finished the TB treatment with the same ART and continued it after.  
Table 1. Location of tuberculosis infection, tuberculostatic treatment, diagnosis and evolution of eight HIV patients treated 
with raltegravir-containing regimens 
Patient no.  Location  Treatmenta  Microbiological diagnosisb  Cure  
     
1  lung  2HRZE + 7HR  yes  yes  
2  hepatosplenic  2HRZE + 7HR  noc  yes  
3  lung  2HRZ + 7HR  yes  yes  
4  lung  2HRZE + 10HR  yes  yes  
5  lung  2HRZE + 7HR  yes  yes  
6  disseminated  2HRZ + 10HR  yes  yes  
7  adenitis  2HRZ + 7HR  yes  yes  
8  lung  2HRZ + 7HR  yes  yes  
     
 
a Numbers correspond to the durations of regimens in months (H = isoniazid, R = rifampicin, Z = pyrazinamide and 
E = ethambutol). 
b Culture identification in Lowenstein–Jensen medium. 
c Caseating granulomas in liver biopsy. 
At the end of TB treatment, all patients previously taking ART remained with HIV-RNA <20 
copies/mL and the median CD4 count was 455 cells/mm
3
 (range 268–666). In those who were not 
under ART when TB was diagnosed, HIV-RNA was undetectable in all cases and the median CD4 
count was 238 cells/mm
3
 (range 208–265). We did not find virological rebounds during the 
follow-up. 
 
To our knowledge, these are the first clinical data reported on the use of raltegravir as part of 
ART in subjects taking rifampicin under real-life conditions. Raltegravir has been shown to be a 
safe drug in many clinical studies, with low rates of hepatotoxicity, even in patients co-infected 
with viral hepatitis;
4
 we had six subjects (75%) with HCV, and TB treatment was completed in all 
cases without liver damage. In spite of treatment with rifampicin, raltegravir maintained its 
virological and immunological efficacy. 
  
Based on pharmacokinetic data and on the good tolerability of raltegravir, the FDA
5
 and the 
EMEA
6
 recommend that the dose of raltegravir be increased to 800 mg twice daily when it is used 
with rifampicin. Our data support these recommendations with real-life clinical experience, 
pending the arrival of results from ongoing clinical trials (e.g. NCT00822315), where two doses of 
raltegravir (400 mg twice daily and 800 mg twice daily) and efavirenz are being compared as part 
of ART in HIV patients with TB receiving rifampicin. 
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